NCT04368728: An ongoing trial by Biontech SE
This trial is ongoing. It must report results 3 months ago.
Full data
| Full entry on ClinicalTrials.gov | NCT04368728 |
|---|---|
| Title | A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 29, 2020 |
| Completion date | Feb. 10, 2023 |
| Required reporting date | Feb. 10, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |